- Home
- BEATW vs FRA Comparison
BEATW vs FRA Comparison
Compare BEATW & FRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- FRA
- Stock Information
- Founded
- BEATW 2015
- FRA 2003
- Country
- BEATW United States
- FRA United States
- Employees
- BEATW N/A
- FRA N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- FRA Investment Bankers/Brokers/Service
- Sector
- BEATW Technology
- FRA Finance
- Exchange
- BEATW Nasdaq
- FRA Nasdaq
- Market Cap
- BEATW N/A
- FRA N/A
- IPO Year
- BEATW N/A
- FRA N/A
- Fundamental
- Price
- BEATW $0.57
- FRA $12.96
- Analyst Decision
- BEATW
- FRA
- Analyst Count
- BEATW 0
- FRA 0
- Target Price
- BEATW N/A
- FRA N/A
- AVG Volume (30 Days)
- BEATW 4.7K
- FRA 165.4K
- Earning Date
- BEATW 03-14-2025
- FRA 01-01-0001
- Dividend Yield
- BEATW N/A
- FRA 11.06%
- EPS Growth
- BEATW N/A
- FRA N/A
- EPS
- BEATW N/A
- FRA N/A
- Revenue
- BEATW N/A
- FRA N/A
- Revenue This Year
- BEATW N/A
- FRA N/A
- Revenue Next Year
- BEATW N/A
- FRA N/A
- P/E Ratio
- BEATW N/A
- FRA N/A
- Revenue Growth
- BEATW N/A
- FRA N/A
- 52 Week Low
- BEATW $0.50
- FRA $11.33
- 52 Week High
- BEATW $0.62
- FRA $13.10
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- FRA 36.20
- Support Level
- BEATW N/A
- FRA $12.96
- Resistance Level
- BEATW N/A
- FRA $13.28
- Average True Range (ATR)
- BEATW 0.00
- FRA 0.11
- MACD
- BEATW 0.00
- FRA 0.02
- Stochastic Oscillator
- BEATW 0.00
- FRA 8.57
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.